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Abstract
Background Cachexia is a complex metabolic syndrome associated with cancer. One of the features of cachexia is the loss of
muscle mass, characterized by an imbalance between protein synthesis and protein degradation. Muscle atrophy is caused by
the hyperactivation of some of the main cellular catabolic pathways, including autophagy. Cachexia also affects the cardiac
muscle. As a consequence of the atrophy of the heart, cardiac function is impaired and mortality is increased. Anti-
cachectic therapy in patients with cancer cachexia is so far limited to nutritional support and anabolic steroids. The use of
the appetite stimulant megestrol acetate (MA) has been discussed as a treatment for cachexia.
Methods In this study the effects of MA were tested in cachectic tumour-bearing rats (Yoshida AH-130 ascites hepatoma).
Rats were treated daily with 100mg/kg of MA or placebo starting one day after tumour inoculation, and for a period of
16 days. Body weight and body composition were assessed at baseline and at the end of the study. Cardiac function was
analysed by echocardiography at baseline and at day 11. Locomotor activity and food intake were assessed before tumour
inoculation and at day 11. Autophagic markers were assessed in gastrocnemius muscle and heart by western blot analysis.
Results Treatment with 100mg/kg/day MA signiﬁcantly attenuated the loss of body weight (9 ± 12%, P< 0.05) and the
wasting of lean and fat mass (7.0 ± 6% and 22.4 ± 3 %, P< 0.001 and P< 0.05, respectively). Administration of
100mg/kg/day MA signiﬁcantly protected the heart from general atrophy (633.8 ± 30mg vs. placebo 474 ± 13mg,
P< 0.001). Tumour-bearing rats displayed cardiac dysfunction, as indicated by the signiﬁcant impairment of the left
ventricular ejection fraction, the left ventricular fractional shortening, the stroke volume, the end dyastolic volume, and the
end systolic volume. In contrast, MA signiﬁcantly improved left ventricular ejection fraction, left ventricular fractional
shortening, and left ventricular end systolic volume. Western blotting analysis showed an upregulation of the autophagic
pathway in the gastrocnemius and hearts of the placebo-treated tumour-bearing rats. Treatment with MA, however, was able
to modulate the autophagic markers (e.g. Beclin-1, p62, TRAF6, and LC3) in the gastrocnemius and in the hearts of tumour-
bearing rats. Most importantly, 100mg/kg/day MA reduced mortality [hazard ratio (HR): 0.44; 95%CI: 0.20–1.00; P = 0.0486].
Conclusions Megestrol acetate improved survival and reduced wasting through a marked downregulation of autophagy,
occurring in both skeletal and heart muscle, the latter effect leading to a signiﬁcant improvement of cardiac function. Our data
suggest that MA might represent a valuable strategy to counteract the development of cancer cachexia-induced cardiomyopathy.
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Introduction
Cachexia is a complex metabolic disorder which has been
shown to occur in late stages of chronic disease including
cancer, characterized by involuntary weight loss caused by
an ongoing wasting of skeletal muscle with or without loss
of adipose tissue.1 In particular, cancer cachexia is a predictor
of poor quality of life, poor treatment response, increased
chemotherapy toxicity, and higher mortality.2 Cachexia
affects 50–80% of patients with cancer and is responsible
for 30% of cancer deaths.3
Generally, loss of muscle mass can be because of a decreased
rate of protein synthesis, an increased rate of protein
degradation or both. However, there is a general consensus that
cancer cachexia is essentially because of a sustained proteolysis.4
Weight loss not only involves skeletal muscle and fat tissue
but multiple organs, including the heart. Although heart atrophy
and functional cardiac abnormalities have been described in
patients with cancer in the late sixties5,6 and even though the
heart, like the skeletal muscle, is a striated muscle, the effects
of cancer cachexia on cardiac atrophy and function have been
undervalued for a long time. The postulate that cancer cachexia
results in cardiac atrophy and cardiac dysfunction, which leads to
congestive heart failure, is nowadays well supported by several
preclinical studies.7–11 However, the process underlying cardiac
atrophy in patients with cancer cachexia is still a matter of
debate. The compromised heart function observed in cancer
cachexia experimental models seems to be related to cardiac
alterations including marked ﬁbrosis and loss of contractile
protein such as troponin I and myosin heavy chain.8,11 The
skeletal and heart muscle atrophies seem to be linked to an
hyperactivation of the ubiquitin-proteasome system (UPS) that
provides a mechanism for selective protein degradation in many
atrophy conditions, including cancer cachexia.4,11–14 However,
UPS is not the only proteolitic pathway that is activated during
cachexia. The activation of autophagy-lysosomal pathway has
been proposed as well.15 Interestingly, the UPS and autophagy
may be coordinated to augment protein degradation.16
Tumour necrosis factor receptor-associated factor 6
(TRAF6) is an adapter protein for toll like receptor-mediated
nuclear factor-κB signalling pathway activation that induces
the production of pro-inﬂammatory cytokines.17 It is formerly
known as a E3 ubiquitine ligase, but it has been reported to
play an important role in coordinating the activation of
autophagy and UPS in atrophying skeletal muscles.18,19
Autophagy is a highly conserved lysosome-driven degradation
pathway of cellular constituents, normally activated at basal level
to maintain cell homeostasis. Emerging data clearly show that
induction of autophagy occurs in the skeletal muscle and in the
heart in different experimental models of cancer cachexia and
that it strongly contributes to the pathogenesis of muscle
wasting.15,20,21 Whether autophagy is also modulated in
cachectic patient is subject to debate. Some reports showed that
autophagy is induced in muscle biopsies of patients with lung
and oesophageal cancer,22,23 but an earlier report, which
investigated some biological markers in patients with cachexia
associated with either chronic obstructive pulmonary disease
or lung cancer, showed that autophagy is signiﬁcantly increased
only in the cachectic skeletal muscle of patients with chronic
obstructive pulmonary disease24 .
Loss of appetite (i.e. anorexia) is frequent in patients with
cachexia and is associated with poor prognosis and reduced
quality of life. Moreover, loss of appetite is a multifactorial
event that includes the increased expression of proin-
ﬂammatory cytokines such as interleukin (IL)-1, IL-6, tumour
necrosis factor or interferon-γ,25 which have been shown to
have effects on peripheral metabolic pathways as lipolysis,
proteolysis as well as on hypothalamic appetite regu-
lation.26,27 However, none of the nutritional strategies so far
proposed for the treatment of cancer cachexia has been
sufﬁcient enough to reverse the syndrome.
Megestrol acetate (MA) is a synthetic, orally active derivative
of the hormone progesterone, originally synthesized in 1963 as a
contraceptive drug.28 It was used in the treatment of breast
cancer and later in the treatment of endometrial cancer. It was
approved in the USA and in several European countries for the
treatment of the anorexia–cachexia syndrome.29 In humans,
MA treatment results in an increased sense of appetite and
improved body weight, as shown in several clinical trials.30–34
Although many reports suggest that the weight gain is only
because of an increase in fat mass,35,36 a recent randomized
phase III clinical trial showed that MA treatment positively
affects muscle mass and performance,37 probably because of
reduced muscle wasting. Indeed, it has been demonstrated that
MA is able to reduce the rate of protein degradation in incubated
isolated skeletal muscle through a mechanism based on the
inhibition of the UPS.38Moreover, MA treatment seems to lower
humoral factors implicated in cachectic response, such as
cytokines.39 Nevertheless, the potential for MA in the treatment
of cachexia-induced cardiomiopathy remains to be better
clariﬁed.
The aim of the present investigation was to assess the
effects of MA on body weight, body composition, cardiac
function, and quality of life as well as survival in a rat Yoshida
AH-130 hepatoma cancer cachexia model. Further, we also
extensively investigated its efﬁcacy in modulating the
autophagic catabolic pathway in the gastrocnemius and in
the hearts of tumour-bearing rats.
Material and methods
Animals
Male Wistar Han rats (Harlan Laboratories, Rossdorf,
Germany) of 8weeks of age and weight of 199.8 ± 2.8 g were
kept under standard laboratory conditions in a speciﬁc-
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pathogen-free animal facility and maintained at 22 ± 2°C with
alternating 12 h light–dark cycle and free access to food and
water. All the experimental procedures were performed in
accordance with the European Commission guidelines for
the animals used for scientiﬁc purposes.
Study design
Rats were randomized into two groups to be injected with
either Yoshida 108 AH-130 hepatoma cells (n = 21) or saline
(n = 11, sham) into the peritoneum. Tumour-bearing rats were
further divided to be treated with placebo (n = 11) or with
100mg/kg/day MA (n = 10). All treatments were given via
gavage once daily over a period of maximum 16days.
Treatment with MA or placebo started one day after tumour
inoculation. All operators involved in the study were blinded
to treatment allocation. One day before tumour inoculation,
baseline body weight, body composition, and echocar-
diographic analysis were assessed. Cardiac function was
analysed again on day 11. Body composition and body weight
were recorded on day 16 or the day of the euthanasia if the
animals had to be sacriﬁced for ethical reasons. At the end
of the study and for each tumour-bearing animals, the tumour
was harvested from the peritoneum and its volume evaluated.
Tumour cell number was determined using a Neubauer
chamber. Organs and tissues were rapidly removed, weighed,
and immediately frozen in liquid nitrogen.
Body composition analysis
Total body fat, lean mass, and body ﬂuids were measured
using the nuclear magnetic resonance spectroscopy device
EchoMRI-700TM (Echo Medical System, Houston, TX, USA).
Each rat was allocated in a tube for the measurement, which
takes 90 s. The analysis of the body structures is based on
nuclear magnetic resonance, which measures the resonance
of magnetic active nuclei in the tissues.40
Spontaneous activity and food intake
Animals were housed individually, and spontaneous
movement was recorded by an infrared monitoring system
(Supermax, Muromachi, Tokyo, Japan) over a 24 h period.
Food intake was also recorded during this period.41
Echocardiographic analysis
Echocardiographic analyses were performed using the high-
resolution Vevo 770 system (VisualSonics Inc, Toronto,
Canada), which was described previously.42 Rats were
anaesthetized with 1.5% isoﬂurane and laid in supine position
on a heated surface to maintain body temperature and with
all legs taped to ECG electrodes. All hair was removed from
the chest using an electrical clipper prior to shave the animals
with a chemical depilatory agent. Recordings were made in B-
mode and M-mode to assess functional parameters, cardiac
function, and dimensions.
Protein extraction and sodium dodecyl sulfate
polyacrylamide gel electrophoresis western blot
Approximately 50mg of heart and gastrocnemius muscle
were separately homogenized in 500μL ice-cold lysis buffer
(20mM Tris–HCl pH 7.5; 150mM NaCl; 1mM EDTA; 1mM
EGTA; 1% Triton X-100; 2,5mM Na4P2O7; 20mM NaF; 1mM
dithiothreitol; 1mM Na3VO4; 1mM β-glycerophosphate;
and 10μL/mL freshly added protease and phosphatase
inhibitor cocktails), centrifuged at 14 000 × g for 20min at
4°C and supernatant was collected. A total of 20μL of the
supernatant was used to determine the total protein
concentration by Bradford assay (Biorad, Hercukes,
California, USA) using bovine serum albumin as a standard.
Proteins were heat denatured for 5min at 95°C in sample-
loading buffer (500mM Tris/HCl, pH 6.8; 30% Glycerol; 10%
sodium dodecyl sulfate; 5% β-mercaptoethanol; and 0024%
bromophenol blu), and 30μg of protein lysate was resolved
by sodium dodecyl sulfate polyacrylamide gel electrophoresis
and transferred to polyvinylidene diﬂuoride membranes (GE
Healthcare, Little Chalfont, UK). Membranes were blocked
with Tris/HCl (pH 7.6) containing 0.1% Tween 20 and 5%
BSA for 2 h and incubated overnight at 4°C with shaking
with the following primary antibodies: Beclin-1 (3738, Cell
Signaling Technology, Boston, USA), ATG12 (4180, Cell
Signaling Technology, Boston, USA), LC3B (NB100-2220,
Novus Biologicals, Littleton, USA), SQSTM1/p62 (5114, Cell
Signaling Technology, Boston, USA), TRAF6 (ab33915, Abcam,
Cambridge, UK), and GAPDH (G9545, Sigma-Aldrich, St. Louis,
Missouri, USA). Membranes were then washed in TBS
(pH 7.6) with 0.1% Tween-20 and incubated with a
ﬂuorescent-conjugated IgG secondary antibody (IRDye
680RD, Fisher Scientiﬁc International Inc., Hampton, New
Hampshire, USA) for 1 h at RT with shaking. Immunoblot
scanning and analyses were performed using an imaging
system (Odyssey Classic, LI-COR Biosciences, Lincoln, NE,
USA). Quantiﬁcation of the bands was performed using the
ImageJ software (NIH, Bethesda, Maryland, USA).
Statistical analysis
Data were analysed with GraphPad PRISM 6.0 (GraphPad
Software, Inc., La Jolla, CA, USA). Results are shown as
mean ± SEM. Normality was tested using D’Agostino
Pearson’s test. Normally distributed data were analysed by
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one way ANOVA followed by Tukey’s test, while data without
normal distribution were analysed using Kruskal–Wallis
analysis of variance and subsequent Dunn’s tests. Survival
was tested by Cox-proportional hazard analysis, hazard ratio
(HR), and 95% conﬁdence interval (CI). A P-value of <0.05
was considered signiﬁcant.
Results
Megestrol acetate improves survival in cancer
cachexia
To assess whether the treatment with MA could have a
positive effect on the lifetime in case of cancer cachexia
development, we analysed the survival of the animals.
Despite of the lack of statistically signiﬁcant effect of MA
treatment on tumour growth (2996 ± 222 × 106 and 2970
± 538 × 106 in placebo and MA-treated animals, respectively),
tumour-bearing rats treated with 100mg/kg/day MA showed
a better survival compared with placebo animals (HR: 0.44;
95%CI: 0.20–1.00; P = 0.0486; Figure 1)
Megestrol acetate reduces wasting in cancer
cachexia
Baseline weight and body composition, i.e. lean and fat mass,
were similar in all the randomized groups before tumour
inoculation (P> 0.2; Figure 2(A–C)). However, while tumour-
bearing rats treated with placebo lost 25 ± 6% of their initial
body weight, non-tumour-bearing, or sham, animals gained
30.4 ± 2% (P< 0.001; Figure 2D). Fat mass was reduced by
64.6 ± 1% in tumour-bearing rats treated with placebo
compared with a gain of 55.4 ± 1% in sham animals
(P< 0.001; Figure 2E). Lean body mass was reduced by 26.1
± 5% in the tumour-bearing rats treated with placebo, while
a muscle mass gain of 27.5 ± 2% was observed in sham rats
(P< 0.001; Figure 2F). Treatment with 100mg/kg/day MA
signiﬁcantly attenuated the loss of body weight (9 ± 12%,
P< 0.05; Figure 2D) and the wasting of fat mass and lean mass
(22.4 ± 3 and 7.0 ± 6% %, P< 0.05 and P< 0.001,
respectively; Figures 2E and 2F) in the tumour-bearing rats.
As expected, the tumour burden had a strong effect on the
individual muscles and tissues. The weights of the gastrocnemius
muscle, soleus muscle, extensor digitalis longus muscle, and
tibialis muscle were signiﬁcantly lower in placebo-treated
tumour-bearing rats compared with sham animal (P< 0.001;
Table 1). Treatment with 100mg/kg/dayMAmarkedly increased
the weights of mixed ﬁbre type gastrocnemius muscle and
tibialis, fast-twitch extensor digitalis longus muscle, and slow-
twitch soleus muscle in the tumour-bearing animals (all
P< 0.001 vs. placebo; Table 1). Moreover, white adipose tissue
and brown adipose tissue were also afftected by tumour
cachexia (both P< 0.001 vs. sham; Table 1). The treatment with
100mg/kg/day MA increased the weight of epididymal white
and brown intrascapular fat in tumour-bearing rats (P< 0.01
vs. placebo, respectively; Table 1).
Figure 1 Kaplan–Meier survival curve and statistical analysis of survival of animals treated with 100mg/kg/day megestrol acetate or placebo. A high
mortality was observed in the placebo group (85%), which was signiﬁcantly reduced by 100mg/kg/day megestrol acetate.
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Indices of morbidity
Baseline 24 h spontaneous activity and food intake were
similar in all groups (all P> 0.2; Fig. S1). Cachectic rats
treated with placebo showed a decreased food intake and
activity on day 11 (P< 0.001 vs. sham; Figure 3A). Treatment
with 100mg/kg/day MA resulted in higher food intake
compared with placebo (P< 0.05; Figure 3A) whilst no effect
on activity was observed (Figure 3B).
Megestrol acetate improves tumour-induced
cardiac dysfunction and heart wasting
Baseline echocardiography was similar in all groups before
tumour inoculation (P> 0.1; Table S1). On day 11, tumour-
bearing rats, treated with placebo, displayed an overall
deterioration of cardiac function compared with baseline sham
animals. However, a number of parameters of cardiac function
were improved by treatment with MA. The left ventricular
Figure 2 Effect of megestrol acetate treatment on body weight and body composition of the tumour-bearing rats. The lost of body weight (D), fat
mass (E), and lean mass (F) are presented as the absolute difference between baseline (A, B, and C) and after removal the tumour at the end of
the study. White bars: sham; black bars: placebo; gray bars: 100mg/kg/day megestrol acetate. The data are presented as mean ± SEM. ***:




:P< 0.001 vs. placebo. Sham n 11, placebo n 11, 100mg/kg/day megestrol acetate n 10.
Table 1. Tissues and muscles weight at the end of the study
Gastrocnemius (mg) Soleus (mg) EDL (mg) BAT (mg) WAT (mg)
Sham 1235±37.9 96.9± 2.7 105.2±3.1 250.2±13.9 1281±66.7
Placebo 736.7±34.1*** 70.1± 1.6*** 62.9±2.6*** 69.9±3.4*** 191.5±9.1***
100mg/kg/day MA 978.9±48 ### 90.1± 4.7 ### 88.6±4.8### 165.6±33.5## 611.7±148.7##
EDL, extensor digitalis longus; WAT, white adipose tissue; BAT, brown adipose tissue.
***P< 0.001 vs. sham.
##P< 0.01.
###P< 0.001 vs. placebo.
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ejection fraction (LVEF) was reduced in tumour-bearing rats
treated with placebo compared with sham animals (58.7 ±2%
vs. sham 75.4±2%, P< 0.01; Figure 4B). Treatment with
100mg/kg/day MA signiﬁcantly improved LVEF (73.5 ±5%,
P< 0.05 vs. placebo, Figure 4B). The left ventricular fractional
shortening (LVFS) was also reduced in tumour-bearing rats
treated with placebo in comparison to control animals (30.25
±1% vs. sham 51.6±1%, P< 0.001; Figure 4C). The treatment
with 100mg/kg/day MA improved signiﬁcantly LVFS (49±4.6%;
P< 0.001 vs. placebo; Figure 4C). The left ventricular stroke
volume (LVSV), the end systolic volume (LVESV) and the end
diastolic volume (LVEDV) were signiﬁcantly impaired in
tumour-bearing rats treated with placebo compared with sham
animals (P< 0.001 for LVSV, P< 0.05 for LVESV and LVEDV vs.
sham; Figure 4D, 4E, and 4F). Whereas the LVSV and the LVEDV
were not improved in the MA-treated group, administration
of 100mg/kg/day MA was able to restore signiﬁcantly the
end systolic volume (66.5 ±8.4μL vs. placebo 98.4±7.6μL;
P< 0.05; Figure 4E). At the end of the study, the average weight
of the hearts of the tumour group treated with placebo was
smaller compared with control rats (474±13mg vs. sham 776
±10mg, P< 0.001; Figure 4A). Moreover, cancer cachexia had
profound effects on cardiac diameters. For instance, a larger left
ventricular internal diameter at end-systole (LVID sys) and a
reduction of the left ventricular internal diameter at end-diastole
(LVID dia) were observed in tumour-bearing rats treated with
placebo compared with sham (P< 0.01 and P< 0.001 for LVID
sys and LVID dia vs. sham, respectively; Figures 4G and 4H).
Administration of 100mg/kg/day MA signiﬁcantly protected
the heart from general atrophy (633.8 ±30mg vs. placebo
474±13mg, P< 0.001; Figure 4A) and from the loss of LV
diameter in systole (2.9 ±0.2mm vs. placebo 3.8±0.1mm,
P< 0.01; Figure 4G) and in diastole (5.8 ±0.1mm vs. placebo
4.5mm, P< 0.001; Figure 4H). Finally, a striking reduction of left
ventricular mass and posterior wall thickness (LVPWT sys), in
systole, was observed in the tumour group treated with placebo
compared with sham rats (both P< 0.01 vs. sham; Figure 4I and
4L). Treatment with 100mg/kg/day MA signiﬁcantly improved
the value of the posterior wall thickness, in systole (2.75
±0.1mm vs. placebo 2.3mm, P< 0.05; Figure 4L).
Megestrol acetate downregulates autophagic
catabolic pathway in the gastrocnemius muscle
and in the heart of tumour-bearing rats
To assess the protective role exerted byMA in the muscle mass
in the context of modulation of autophagic degradation,
autophagic markers, in the gastrocnemius and in the heart of
the tumour-bearing rats and in the control animals, were
analysed. Although ATG12-ATG5 and Beclin-1, which play an
important role in the initial steps and in the formation of the
autophagosome, were not upregulated in the gastrocnemius
muscle of tumour-bearing rats treated with placebo compared
with control animals (Figures 5A and 5B), a signiﬁcant increase
of microtubule-associated protein 1 light chain 3B isoform I
(LC3B-I) and its lipidated form LC3B-II was detected (both
P< 0.001 vs. sham; Figures 5E and 5F). In addition, the ratio
of LC3B-II to LC3B-I was measured as a marker of LC3 cleavage
and therefore activation of the autophagic pathway. In the
gastrocnemius, the LC3 ratio was increased in the tumour
group treated with placebo compared with the control group
(P< 0.05 vs. sham, Figure 5G). Moreover, p62, as a marker of
substrate sequestration into autophagosome, was assayed.
Levels of p62 were signiﬁcantly higher (P< 0.01; Figure 5C)
in the skeletal muscle of tumour-bearing rats treated with
placebo than in sham rats. In addition, levels of the pro-
tein TRAF6 were greater in the gastrocnemius muscle of
Figure 3 Effect of megestrol acetate treatment on (A) food intake and (B) spontaneous activity of tumour- bearing rats. Activity was not affected by
the treatment, while food intake was increased by 100mg/kg/day megestrol acetate.White bars: sham; black bars: placebo; gray bars: 100mg/kg/day
megestrol acetate. The data are presented as mean ± SEM. ***:P< 0.001, *P< 0.05 vs. sham; #:P< 0.05 vs. placebo. Sham n 11, placebo n 11,
100mg/kg/day megestrol acetate n 10.
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Figure 4 The effect of megestrol acetate on cardiac function and heart wasting of cachectic rats. (A) At the end of the study, the weight of the heart in
the tumour group treated with placebo was smaller compared with control rats. Treatment with 100mg/kg/day MA signiﬁcantly protected the hearts
from atrophy. (B) Left ventricular ejection fraction and (C) left ventricular fractional shortening were reduced in tumour-bearing rats treated with
placebo compared with sham animals. Treatment with 100mg/kg/day MA signiﬁcantly improved left ventricular ejection fraction and left ventricular
fractional shortening. (D) The left ventricular stroke volume, (E) the left ventricular end systolic volume, and (F) the left ventricular end diastolic volume
were signiﬁcantly impaired in tumour-bearing rats treated with placebo compared with sham animals. Administration of 100mg/kg/day MA was able
to improve signiﬁcantly the left ventricular end systolic volume (E), whereas the left ventricular stroke volume and the left ventricular end diastolic
volume were not improved (D and F). (G) A larger left ventricular internal systolic diameter and (H) a reduction of the left ventricular internal diastolic
diameter were observed in tumour-bearing rats treated with placebo compared with sham rats. Treatment with 100mg/kg/day MA signiﬁcantly
protected from the loss of left ventricular diameter in systole (G) and in diastole (H). (I) A striking reduction of left-ventricular mass and left ventricular
posterior wall thickness, in systole, was observed in the tumour group treated with placebo compared with sham rats. Treatment with 100mg/kg/day
MA signiﬁcantly improved the value of the posterior wall thickness, in systole. The data are presented as mean ± SEM. *:P< 0.05, **:P< 0.01, ***:
P< 0.001 vs. sham; #:P< 0.05, ##:P< 0.01, ###:P< 0.001 vs. placebo. Sham n 11, placebo n 11, 100mg/kg/day megestrol acetate n 10.
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placebo-treated tumour-bearing rats than in sham rats
(P< 0.001; Figure 5D). Treatment with 100mg/kg/day MA
signiﬁcantly reduced the autophagic markers in the
gastrocnemius of the tumour-bearing rats. Indeed, LC3 was
downregulated in both forms as well as LC3B-II/LC3B-I ratio
(P< 0.001 for LC3B-I and LC3B-II, P< 0.05 for LC3B-II/LC3B-I
vs. placebo, respectively; Figure 5E, 5F, and 5G). Similarly,
p62 levels were downregulated as a result of megesterol
acetate treatment (P< 0.05 vs. placebo; Figure 5C). Finally,
TRAF6 protein levels demonstrated no signiﬁcant difference
between placebo and MA-treated tumour rats (Figure 5D).
Heart ATG12-ATG5 complex levels were not signiﬁcantly
different between any groups. However, heart Beclin-1
protein levels were signiﬁcantly higher (P< 0.05; Figure 6B)
in the tumour group treated with placebo compared with
the sham group. Treatment with 100mg/kg/day MA
signiﬁcantly reduced Beclin-1 levels in the tumour-bearing
rats (P< 0.01 vs. placebo; Figure 6B). LC3B-I expression did
not change in the hearts of the tumour-bearing rats treated
with placebo (Figure 6E), whereas LC3B-II levels were
signiﬁcantly elevated compared with sham animals (P< 0.01;
Figure 6F). The LC3 ratio was increased (P< 0.001; Figure 6G)
in the tumour group treated with placebo compared with the
control rats. Administration of 100mg/kg/day MA
signiﬁcantly reduced LC3B-I (P< 0.01 vs. placebo; Figure
6E), LC3B-II (P< 0.001 vs. placebo; Figure 6F), and the
Figure 5 Megestrol acetate downregulates autophagy in the gastrocnemius muscle of tumour-bearing rats. (A) ATG12-ATG5 and (B) Beclin were not
upregulated in the gastrocnemius muscle of tumour-bearing rats treated with placebo compared with control animals. (C) Levels of p62 were
signiﬁcantly higher in tumour-bearing rats treated with placebo than in sham rats. Treatment with 100mg/kg/day MA signiﬁcantly downregulated
p62 levels. (D) TRAF6 levels were greater in placebo-treated tumour-bearing rats than in sham rats. Protein levels were not downregulated as a result
of megesterol acetate treatment. (E) LC3B-I, (F) its lipidated form LC3B-II, and (G) the LC3 ratio were upregulated in placebo-treated tumour-bearing
rats than in sham rats. Treatment with 100mg/kg/day MA signiﬁcantly downregulated LC3 in both forms (LC3-II and LC3-II), as well as LC3B-II/LC3B-I
ratio was downregulated. The data are presented as mean ± SEM. *:P< 0.05, **:P< 0.01, ***:P< 0.001 vs. sham; #:P< 0.05, ###:P< 0.001 vs. placebo.
Sham n 11, placebo n 11, 100mg/kg/day megestrol acetate n 10.
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LC3B-II/LC3B-I ratio in the hearts of the tumour group
(P< 0.05 vs. placebo; Figure 6G). In addition, p62 heart
expression was increased in the placebo-treated tumour
group compared with sham animals (P< 0.01; Figure 6C),
whereas 100mg/kg/day MA signiﬁcantly reduced p62
accumulation (P< 0.05 vs. placebo; Figure 6C). Although,
heart TRAF6 expression had an increasing trend, which did
not reach any statistical signiﬁcance, in tumour-bearing rats
of the placebo group compared with sham rats (Figure 6D),
administration of 100mg/kg/day MA signiﬁcantly down-
regulated the expression of TRAF6 in the tumour group
(P< 0.01 vs. placebo; Figure 6D).
Discussion
Tumour burden induces a severe wasting of skeletal muscle and
fat tissue. In the present work we have demonstrated that
Yoshida hepatoma is also associated with a form of cachexia,
which induces cardiomyopathy in rats. In cancer cachexia,
skeletal muscle and heart wasting are associated with an
hyperactivation of autophagy.15,20,21 We supported these data
and, in addition, we demonstrated, for the ﬁrst time, that MA
downregulates autophagy in skeletal and heart muscle with a
signiﬁcant improvement of cardiac function.
Figure 6 Megestrol acetate downregulates autophagy in the heart of tumour-bearing rats. (A) ATG12-ATG5 complex levels were not different between
any groups. (B) Beclin-1 was signiﬁcantly higher in the cachectic rats treated with placebo compared with the sham group. Treatment with 100mg/kg/
day MA signiﬁcantly reduced Beclin-1 levels in the tumour-bearing rats. (C) The p62 expression was increased in the placebo-treated tumour group
compared with sham animals, whereas 100mg/kg/day MA signiﬁcantly reduced p62 accumulation. (D) TRAF6 expression had an increasing trend,
in the cachectic animals treated with placebo compared with sham rats. Treatment with 100mg/kg/day MA signiﬁcantly downregulated the
expression of TRAF6 in the tumour group. (E) LC3B-I expression did not change in the hearts of the tumour-bearing rats treated with placebo, whereas
(F) LC3B-II levels were signiﬁcantly elevated compared with sham rats. (G) The LC3 ratio was increased in the tumour group treated with placebo
compared with the control rats. Treatment with 100mg/kg/day MA signiﬁcantly reduced LC3B-I, LC3B-II levels and the LC3B-II/LC3B-I ratio of the













placebo. Sham n 11, placebo n 11, 100mg/kg/day megestrol acetate n 10.
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Here, we show that MA attenuates the loss of body weight
in the Yoshida AH-130 hepatoma cancer cachexia model
without effecting tumour growth. The AH-130 hepatoma rat
model also develops a marked anorexia,43 a condition often
associated with cachexia in humans.1 Previous reports have
shown that intake of the drug resulted in an increased sense
of appetite in rodents38,44 and in humans.35,36 The precise
mechanism of action of MA is unknown, but its effect may
be partially mediated by the neuropeptide Y, a potent centrally
acting appetite stimulant.45 Food intake and spontaneous activity
are recognized as good indicators of the quality of life in animals.46
In our study, treatment with MA had a positive effect on food
intake, but it did not enhance physical performance, further
supporting the previously described failure of MA to totally
improve quality of life.47 Although, several evidences30–34 indicate
the occurrence of a beneﬁt in body weight gain subsequently to
MA treatment, this seems to correlate with an increase only in
fat mass,35,36 with a direct action on adipocyte differentiation.48
However, other ﬁndings showed an increased bio-
availability of IGF-I during MA treatment, which may
contribute to the anabolic action of the drug on skeletal
muscle in patients with advanced cancer49 and a reduction
of the muscle wasting process through a mechanism based
on the modulation of the UPS.38 Here, we show for the ﬁrst
time that MA may inhibit, to some extend, muscle atrophy
by decreasing the catabolic pathway of autophagy.
Autophagy has been implicated in hearts and skeletal
muscles wasting in several models of cancer cachexia.50
We also demonstrated the hyperactivation of autophagy in rats
bearing Yoshida AH-130 hepatoma by changes occurring in the
well-recognized biomarkers of this catabolic pathway. In particular,
we found MA-associated positive changes in Beclin-1, an inducer
of the autophagosome formation, in LC3B-I to LC3B-II conversion,
which was measured as a marker of autophagosome abundance,
in p62, a marker of substrate sequestration and ﬁnally in TRAF6,
an E3 ubiquitin ligase, involved in activation of autophagy and
UPS in atrophying skeletal muscle.19
In particular, we found that in the skeletal muscle,
autophagy was associated with increased LC3B lipidation
and p62 accumulation, whereas no changes in ATG12-ATG5
or Beclin-1 levels were observed. Levels of p62 usually
inversely correlate with autophagic degradation,51 although
our reports, and other studies clearly showed that this
marker could also be increased in many atrophic conditions
upon activation of autophagy.15 The scaffold protein p62 assumes
a main role in recognition of ubiquitinylated proteins or
depolarized mitochondria during selective autophagy;
interestingly, it has been described that p62 can also deliver
ubiquitinylated cargos to the proteasome.52 Looking for proteins
that play a regulatory role in activation of signalling cascades
related to muscle atrophy, TRAF6, might potentially be an
upstream regulator for the activation of pathways involved in loss
of muscle proteins in conditions of wasting.19 TRAF6 expression is
increased in several models of muscle atrophy, including fasting
and cancer, leading to downstream activation of major catabolic
pathways in skeletal muscle, including autophagy.18,53 In
accordance with these reports, in the gastrocnemius of the
Yoshida AH-130 hepatoma model we found high levels of TRAF6.
Our evidence supports the hypothesis that TRAF6 could modulate
the autophagy also in this model. Although MA reduced skeletal
muscle atrophy, modulating some steps of the complex
autophagic pathway, the drug did not have a direct effect on
TRAF6, at least in the gastrocnemius.
Cardiac atrophy has been described in several models of
cancer cachexia.11,20,21 Our results support and extend these
data. We indeed observed a reduction of the posterior wall
thickness, LV mass, and total heart weight in cachectic rats,
which are features of cardiac atrophy. MA administration
attenuated this wasting. Although the exact pathways leading
to cardiac wasting are not fully elucidated, our results support
the idea that the catabolic signalling pathways activated in the
skeletal muscle are responsible for the atrophy of the heart.54
In this scenario, autophagy has been proposed as the main
catabolic pathway regulated in the heart, whereas UPS has a
high basal activity.55 However, it is likely that the activation
of the main proteolitic pathways may differ between cancer
models since using the Yoshida AH-130 hepatoma model,
increased UPS activity was previously described.11
On the basis of the observation in the skeletal muscle and
consistent with our ﬁndings of decreased cardiac mass, we
observed that the heart atrophy in Yoshida AH-130 was
associated with elevated level of Beclin-1, p62, and LC3,
suggesting that changes in cardiac mass is clearly associated
with autophagy. The results presented in our study clearly
demonstrated that MA may inhibit atrophic mechanism,
modulating autophagy also in the heart. MA might reduced
the expression of humoral factors involved in chronic
inﬂammation and oxidative stress, and contributing to the
activation of protein degradation in muscle.27,50 Although
new studies are needed to better clarify these ﬁndings, we
can further postulate that the decreased expression of
TRAF6 in the hearts of cachectic rats treated with MA might
be because of a reduction expression of pro-inﬂammatory
cytokines, because TRAF6 suppression resulted in reduced
IL-1β and IL-6 expression.56 Overall, cardiac atrophy is
associated with a clear heart dysfunction because of tumour
growth and cachexia in the Yoshida AH-130 model. The
cardiac parameters that we analysed in this study are signs
for myocardial dysfunction, and they are similar to previous
results.57 Although the cardioprotective effect of MA has
not been described so far, treatment with the drug could
signiﬁcantly improve LVEF, and LVFS of the cachectic rats
compared with the placebo group, and therefore, it may
prevent the development of cancer cachexia-induced
cardiomyopathy.10,57,58 Cardiac remodelling is a clear event
in tumour-bearing rats and mice.7,8,50 Even though our
study is lacking some histological evidences, adverse cardiac
remodelling in tumour-bearing rats, i.e. the reduction of
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LVID dia and LVID sys, was signiﬁcantly attenuated by MA
treatment. Protecting heart and its function seems to be
crucial in cachexia.11 Cardiac function was dramatically
improved by treatment with MA, and this is likely
contributed to the survival beneﬁts observed in our study.
In conclusion, our data show the action of MA, an appetite
stimulant, on body weight and cardiac function in the well-known
Yoshida AH-130 hepatoma rat model of cancer cachexia. In
particular, MA improved survival and reduced wasting through a
marked downregulation of autophagy, occurring in both skeletal
and heart muscles, the latter effect leading to a signiﬁcant
improvement of cardiac function. Thus, our data suggest that
MA might represent a valuable strategy to counteract the
development of cancer cachexia-induced cardiomyopathy.
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